A Phase 2 interventional study of D-2570 Tablet and Placebo Tablets in Psoriasis, sponsored by InventisBio Co., Ltd. Recruiting at 20 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-07-09.
Sponsored by InventisBio Co., Ltd · Phase 2, Interventional, and Treatment
A Study looking at the safety and efficacy of D-2570 in Participants with Plaque Psoriasis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Participants with Moderate to Severe Plaque Psoriasis
2,028 studies on the registry are indexed under Psoriasis; 275 are open to participants now.
This study's planned enrollment of 75 is close to the median of 75 across 1,565 interventional studies indexed under Psoriasis.
Browse Psoriasis studies →InventisBio Co., Ltd is the lead sponsor of 34 studies on the registry; 11 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Low dose of D-2570
Drug: D-2570 Tablet
medium dose level of D-2570
Drug: D-2570 Tablet
Placebo arm
Drug: Placebo Tablets
Active Treatment
Identical Tablet
Improvement in PASI-90
Proportion of participants achieving at least a 90% improvement from baseline in Psoriasis Area and Severity Index (PASI-90) at Week 12
Time frame: Assessment completed after 12 weeks of treatment/placebo
Plan to share: Undecided
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: D-2570